Growing evidence suggests that the gut microbiome and diabetes are intricately linked, with gut bacteria influencing glucose metabolism, insulin resistance, and inflammation. Dysbiosis, or microbial imbalance, has been associated with an increased risk of type 2 diabetes and metabolic dysfunction. Short-chain fatty acids produced by beneficial bacteria play a role in improving insulin sensitivity and regulating appetite. Probiotics, prebiotics, and dietary interventions targeting gut microbiota composition offer promising therapeutic potential. Advances in metagenomics and microbiome research continue to uncover mechanisms by which gut flora modulate metabolic health. Understanding these interactions may lead to novel microbiome-based strategies for diabetes prevention and treatment.
Submit your abstract Today
